123 related articles for article (PubMed ID: 11914643)
1. Combined analysis of two phase II trials in patients with primary and advanced breast cancer with epidoxorubicin and docetaxel+granulocyte colony stimulating factor.
Wenzel C; Locker GJ; Schmidinger M; Rudas M; Taucher S; Gnant MF; Jakesz R; Steger GG
Anticancer Drugs; 2002 Jan; 13(1):67-74. PubMed ID: 11914643
[TBL] [Abstract][Full Text] [Related]
2. Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF.
Wenzel C; Bartsch R; Hussian D; Pluschnig U; Altorjai G; Zielinski CC; Lang A; Haid A; Jakesz R; Gnant M; Steger GG
Breast Cancer Res Treat; 2007 Jul; 104(1):109-14. PubMed ID: 17061042
[TBL] [Abstract][Full Text] [Related]
3. Pathological complete response rates comparing 3 versus 6 cycles of epidoxorubicin and docetaxel in the neoadjuvant setting of patients with stage II and III breast cancer.
Reitsamer R; Peintinger F; Prokop E; Hitzl W
Anticancer Drugs; 2005 Sep; 16(8):867-70. PubMed ID: 16096435
[TBL] [Abstract][Full Text] [Related]
4. Preoperative therapy with epidoxorubicin and docetaxel plus trastuzumab in patients with primary breast cancer: a pilot study.
Wenzel C; Hussian D; Bartsch R; Pluschnig U; Locker GJ; Rudas M; Gnant MF; Jakesz R; Zielinkski CC; Steger GG
J Cancer Res Clin Oncol; 2004 Jul; 130(7):400-4. PubMed ID: 15168107
[TBL] [Abstract][Full Text] [Related]
5. Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14.
Steger GG; Galid A; Gnant M; Mlineritsch B; Lang A; Tausch C; Rudas M; Greil R; Wenzel C; Singer CF; Haid A; Pöstlberger S; Samonigg H; Luschin-Ebengreuth G; Kwasny W; Klug E; Kubista E; Menzel C; Jakesz R;
J Clin Oncol; 2007 May; 25(15):2012-8. PubMed ID: 17513805
[TBL] [Abstract][Full Text] [Related]
6. Preoperative chemotherapy with epidoxorubicin, docetaxel and capecitabine plus pegfilgrastim in patients with primary breast cancer.
Wenzel C; Bartsch R; Locker GJ; Hussian D; Pluschnig U; Sevelda U; Gnant MF; Jakesz R; Zielinski CC; Steger GG
Anticancer Drugs; 2005 Apr; 16(4):441-5. PubMed ID: 15746581
[TBL] [Abstract][Full Text] [Related]
7. Phase I/II trial of weekly epidoxorubicin and docetaxel (wED) in the neoadjuvant and palliative treatment of patients with breast cancer.
Wenzel C; Locker GJ; Pluschnig U; Zielinski CC; Rudas M; Oberhuber G; Gnant MF; Taucher S; Jakesz R; Steger GG
Cancer Chemother Pharmacol; 2002 Aug; 50(2):155-9. PubMed ID: 12172982
[TBL] [Abstract][Full Text] [Related]
8. Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study.
Pagani O; Sessa C; Nolè F; Crivellari D; Lombardi D; Thürlimann B; Hess D; Borner M; Bauer J; Martinelli G; Graffeo R; Zucchetti M; D'Incalci M; Goldhirsch A
Ann Oncol; 2000 Aug; 11(8):985-91. PubMed ID: 11038035
[TBL] [Abstract][Full Text] [Related]
9. Biweekly docetaxel and vinorelbine with granulocyte colony-stimulating factor support for patients with anthracycline-resistant metastatic breast cancer.
Gómez-Bernal A; Cruz JJ; Olaverri A; Arizcun A; Martín T; Rodríguez CA; Martín G; Fonseca E; Sánchez P
Anticancer Drugs; 2005 Jan; 16(1):77-82. PubMed ID: 15613908
[TBL] [Abstract][Full Text] [Related]
10. Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer.
Pagani O; Sessa C; Martinelli G; Crivellari D; Buonadonna A; Thürlimann B; Hess D; Borner M; Bauer J; Zampino G; Zimatore M; Graffeo R; Riva A; Goldhirsch A
Ann Oncol; 1999 May; 10(5):539-45. PubMed ID: 10416003
[TBL] [Abstract][Full Text] [Related]
11. Treatment of advanced, refractory breast cancer with alternating docetaxel and epirubicin/cyclophosphamide plus human granulocyte colony-stimulating factor.
Kwasny W; Kornek G; Haider K; Valencak J; Ulrich-Pur H; Penz M; Lang F; Depisch D; Scheithauer W
Breast Cancer Res Treat; 2000 Oct; 63(3):235-41. PubMed ID: 11110057
[TBL] [Abstract][Full Text] [Related]
12. Biweekly docetaxel and vinorelbine in anthracycline-resistant metastatic breast cancer: a multicenter phase II study.
Gómez-Bernal A; Cruz JJ; García-Palomo A; Arizcun A; Pujol E; Diz P; Martín G; Fonseca E; Sánchez P; Rodríguez C; del Barco E; López Y
Am J Clin Oncol; 2003 Apr; 26(2):127-31. PubMed ID: 12714881
[TBL] [Abstract][Full Text] [Related]
13. [Clinical phase II-evaluation of neoadjuvant, cytostatic combination chemotherapy with docetaxel and epidoxorubicin in female breast cancer patients (T1-4, N0-2, M0)].
Wenzel C; Schmidinger M; Locker GJ; Taucher S; Gnant M; Jakesz R; Steger GG
Wien Klin Wochenschr; 1999 Oct; 111(20):843-50. PubMed ID: 10586489
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer.
Cascinu S; Graziano F; Barni S; Labianca R; Comella G; Casaretti R; Frontini L; Catalano V; Baldelli AM; Catalano G
Br J Cancer; 2001 Feb; 84(4):470-4. PubMed ID: 11207039
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of vinorelbine and docetaxel with granulocyte colony-stimulating factor support in the treatment of metastatic breast cancer.
Ibrahim NK; Rahman Z; Valero V; Murray JL; Frye D; Hortobagyi GN
Cancer Invest; 2002; 20(1):29-37. PubMed ID: 11852999
[TBL] [Abstract][Full Text] [Related]
16. High-dose epirubicin plus docetaxel at standard dose with lenograstim support as first-line therapy in advanced breast cancer.
Milla-Santos A; Milla L; Rallo L; Solano V
Am J Clin Oncol; 2001 Apr; 24(2):138-42. PubMed ID: 11319287
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: efficacy and safety in a prospective, randomized, phase II study.
Chen J; Yao Q; Li D; Zhang J; Wang T; Yu M; Zhou X; Huan Y; Wang J; Wang L
BMC Cancer; 2013 May; 13():248. PubMed ID: 23693018
[TBL] [Abstract][Full Text] [Related]
18. A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer.
Perez EA; Geeraerts L; Suman VJ; Adjei AA; Baron AT; Hatfield AK; Maihle N; Michalak JC; Kuross SA; Kugler JW; Lafky JM; Ingle JN
Ann Oncol; 2002 Aug; 13(8):1225-35. PubMed ID: 12181246
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibiotics.
Rischin D; Ackland SP; Smith J; Garg MB; Clarke S; Millward MJ; Toner GC; Zalcberg J
Ann Oncol; 2002 Nov; 13(11):1810-8. PubMed ID: 12419756
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel and epirubicin supported by granulocyte colony-stimulating factor first-line in advanced breast cancer.
Polyzos A; Tsavaris N; Kosmas C; Gogas H; Vadiaka M; Markopoulos C; Giannopoulos A; Kalahanis N; Stamatiadis D; Kouraklis G; Karatzas G; Liapis C; Syrigos K
Anticancer Res; 2003; 23(3C):2917-23. PubMed ID: 12926135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
